Vera Therapeutics
- Biotech or pharma, therapeutic R&D
Atacicept (a B cell modulator) is currently in Phase 3 ongoing trial for IgA Nephropathy (IgAN). Atacicept showed eGFR stabilization through 104 weeks in prior Phase 2b study and holds disease modifying potential.
)
)
){kind=logo}
){kind=logo}
){kind=logo}